Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. more
Time Frame | UTHR | Sector | S&P500 |
---|---|---|---|
1-Week Return | -0.62% | -2.12% | -3% |
1-Month Return | -1.3% | -3.42% | -0.73% |
3-Month Return | 1.86% | -11.13% | 2.87% |
6-Month Return | 16.38% | -5.74% | 7.17% |
1-Year Return | 59.45% | 3.97% | 25.31% |
3-Year Return | 77.82% | 1.05% | 28.38% |
5-Year Return | 297.81% | 34.37% | 81.89% |
10-Year Return | 168.7% | 97.88% | 183.27% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 1.45B | 1.48B | 1.69B | 1.94B | 2.33B | [{"date":"2019-12-31","value":62.25,"profit":true},{"date":"2020-12-31","value":63.73,"profit":true},{"date":"2021-12-31","value":72.42,"profit":true},{"date":"2022-12-31","value":83.19,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 117.60M | 108.10M | 122.50M | 146.70M | 257.50M | [{"date":"2019-12-31","value":45.67,"profit":true},{"date":"2020-12-31","value":41.98,"profit":true},{"date":"2021-12-31","value":47.57,"profit":true},{"date":"2022-12-31","value":56.97,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 1.33B | 1.38B | 1.56B | 1.79B | 2.07B | [{"date":"2019-12-31","value":64.31,"profit":true},{"date":"2020-12-31","value":66.43,"profit":true},{"date":"2021-12-31","value":75.51,"profit":true},{"date":"2022-12-31","value":86.45,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 91.88% | 92.71% | 92.73% | 92.42% | 88.94% | [{"date":"2019-12-31","value":99.08,"profit":true},{"date":"2020-12-31","value":99.98,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.67,"profit":true},{"date":"2023-12-31","value":95.91,"profit":true}] |
Operating Expenses | 1.52B | 781.60M | 1.01B | 809.90M | 885.10M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":51.46,"profit":true},{"date":"2021-12-31","value":66.31,"profit":true},{"date":"2022-12-31","value":53.32,"profit":true},{"date":"2023-12-31","value":58.28,"profit":true}] |
Operating Income | (187.60M) | 593.60M | 555.90M | 979.70M | 1.18B | [{"date":"2019-12-31","value":-15.83,"profit":false},{"date":"2020-12-31","value":50.1,"profit":true},{"date":"2021-12-31","value":46.92,"profit":true},{"date":"2022-12-31","value":82.68,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Total Non-Operating Income/Expense | 24.90M | 50.40M | 36.10M | (16.30M) | 192.80M | [{"date":"2019-12-31","value":12.91,"profit":true},{"date":"2020-12-31","value":26.14,"profit":true},{"date":"2021-12-31","value":18.72,"profit":true},{"date":"2022-12-31","value":-8.45,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (165.00M) | 638.90M | 593.90M | 950.60M | 1.27B | [{"date":"2019-12-31","value":-12.95,"profit":false},{"date":"2020-12-31","value":50.14,"profit":true},{"date":"2021-12-31","value":46.61,"profit":true},{"date":"2022-12-31","value":74.6,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income Taxes | (60.50M) | 124.10M | 118.10M | 223.30M | 289.50M | [{"date":"2019-12-31","value":-20.9,"profit":false},{"date":"2020-12-31","value":42.87,"profit":true},{"date":"2021-12-31","value":40.79,"profit":true},{"date":"2022-12-31","value":77.13,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (104.50M) | 514.80M | 475.80M | 727.30M | 984.80M | [{"date":"2019-12-31","value":-10.61,"profit":false},{"date":"2020-12-31","value":52.27,"profit":true},{"date":"2021-12-31","value":48.31,"profit":true},{"date":"2022-12-31","value":73.85,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income From Continuous Operations | (104.50M) | 514.80M | 475.80M | 727.30M | 984.80M | [{"date":"2019-12-31","value":-10.61,"profit":false},{"date":"2020-12-31","value":52.27,"profit":true},{"date":"2021-12-31","value":48.31,"profit":true},{"date":"2022-12-31","value":73.85,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (104.50M) | 514.80M | 475.80M | 727.30M | 984.80M | [{"date":"2019-12-31","value":-10.61,"profit":false},{"date":"2020-12-31","value":52.27,"profit":true},{"date":"2021-12-31","value":48.31,"profit":true},{"date":"2022-12-31","value":73.85,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
EPS (Diluted) | 11.28 | 11.58 | 10.03 | 15.02 | 19.84 | [{"date":"2019-12-31","value":56.85,"profit":true},{"date":"2020-12-31","value":58.37,"profit":true},{"date":"2021-12-31","value":50.55,"profit":true},{"date":"2022-12-31","value":75.71,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
UTHR | |
---|---|
Cash Ratio | 3.81 |
Current Ratio | 4.58 |
Quick Ratio | 4.41 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
UTHR | |
---|---|
ROA (LTM) | 11.89% |
ROE (LTM) | 18.81% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
UTHR | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.14 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.86 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
UTHR | |
---|---|
Trailing PE | 15.82 |
Forward PE | 12.82 |
P/S (TTM) | 5.83 |
P/B | 2.62 |
Price/FCF | 53 |
EV/R | 4.73 |
EV/Ebitda | 8.38 |
PEG | 0.73 |
United Therapeutics Corporation (UTHR) share price today is $359.58
Yes, Indians can buy shares of United Therapeutics Corporation (UTHR) on Vested. To buy United Therapeutics Corporation from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in UTHR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of United Therapeutics Corporation (UTHR) via the Vested app. You can start investing in United Therapeutics Corporation (UTHR) with a minimum investment of $1.
You can invest in shares of United Therapeutics Corporation (UTHR) via Vested in three simple steps:
The 52-week high price of United Therapeutics Corporation (UTHR) is $417.81. The 52-week low price of United Therapeutics Corporation (UTHR) is $208.62.
The price-to-earnings (P/E) ratio of United Therapeutics Corporation (UTHR) is 15.8173
The price-to-book (P/B) ratio of United Therapeutics Corporation (UTHR) is 2.62
The dividend yield of United Therapeutics Corporation (UTHR) is 0.00%
The market capitalization of United Therapeutics Corporation (UTHR) is $16.08B
The stock symbol (or ticker) of United Therapeutics Corporation is UTHR